Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a shorter TB drug combo beat Drug-Resistant TB?

NCT ID NCT05007821

Completed Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two different doses of the antibiotic linezolid, combined with three other drugs (bedaquiline, delamanid, and clofazimine), in 138 people with drug-resistant pulmonary tuberculosis. The goal was to see which dose worked better at clearing the infection and was easier to tolerate. Researchers also measured drug levels in the blood to understand how the body processes the medicines.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Linezolid, bedaquiline, delamanid, and clofazimine (antibiotic combination)
What this could lead to
If successful, this could help identify a safer, shorter treatment regimen for drug-resistant tuberculosis, reducing side effects and improving cure rates.
What could go wrong
This is a phase 2 trial with only 138 participants, so results are preliminary. The higher linezolid dose may cause more side effects, and the regimen may not work for all types of drug-resistant TB.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG-RESISTANT PULMONARY TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

drug-resistant tuberculosis multidrug-resistant tuberculosis pulmonary tuberculosis tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUBERCULOSIS TUBERCULOSIS, MULTIDRUG-RESISTANT TUBERCULOSIS, PULMONARY

Contacts and locations

Locations

  • Barranco CRS (Site ID: 11301)

    Lima, 15063, Peru

  • Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS (Site ID: 31784)

    Chiang Mai, 50200, Thailand

  • De La Salle Health Science Institute Angelo King Medical Research Center (DLSHSI-AKMRC) (Site ID: 31981)

    Cavite, 4114, Philippines

  • Durban International CRS (Site ID: 11201)

    Durban, KwaZulu-Natal, 4052, South Africa

  • GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS (Site ID: 31730)

    Port-au-Prince, HT-6110, Haiti

  • Gaborone CRS (Site ID: 12701)

    Gaborone, South-East District, Botswana

  • Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site ID: 12101)

    Rio de Janeiro, 21040-360, Brazil

  • Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS (Site ID: 30022)

    Port-au-Prince, HT-6110, Haiti

  • Rustenburg CRS (Site ID: 31684)

    Rustenburg, North West, 0300, South Africa

  • South African Tuberculosis Vaccine Initiative (SATVI) CRS (Site ID: 31793)

    Cape Town, Western Cape, 7705, South Africa

  • Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site ID: 31802)

    Pathum Wan, Bangkok, 10330, Thailand

  • University of Cape Town Lung Institute (UCTLI) CRS (Site ID: 31792)

    Cape Town, Western Cape, 7700, South Africa

  • Wits Helen Joseph Hospital CRS (Wits HJH CRS) (Site ID: 11101)

    Johannesburg, Gauteng, 2092, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.